AIM-listed Scancell seeks Nasdaq access via all-share deal with US-listed Neuphoria, pending final terms and financing.
Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF, FRA:SCP) has confirmed advanced negotiations for a reverse merger with US-listed Neuphoria Therapeutics. The proposed all-share transaction aims to secure a Nasdaq listing, enhancing visibility among US investors.
The company is also in separate discussions for equity and debt financing to fund a global phase III study for its lead cancer drug candidate, iSCIB1+. Scancell cautioned that both the merger and financing remain subject to final terms and definitive agreements.
No certainty exists that the deal or funding will materialize, the company added.